Facility construction and start up for commercial scale manufacturing of monoclonal antibodies - A case study
|
|
- Bernice Wilkins
- 8 years ago
- Views:
Transcription
1 24 th Interphex, Japan, Technical Conference June 29 th, 2011 Michael Brown Facility construction and start up for commercial scale manufacturing of monoclonal antibodies - A case study
2 Lonza AG Financially stable / global footprint CHF 2.7 billion (2010 sales) 27 facilities; 8,300 employees Markets Served Bioresearch Pharma & Biotech Nutrition Personal Care Microbial Control Agriculture Materials Science Global leader in custom manufacturing Chemical and biological APIs, cell therapy Lead optimization through market supply slide 2
3 slide 3 Lonza Custom Manufacturing 52% Life Sciences Portfolio (over 90%) 8% Exclusive Custom Synthesis Manufacturing & Biopharmaceuticals Custom manufacturing and development services for active ingredients Bioscience Life Science Ingredients Biology-based products for customers in R&D, production and quality control Nutrition Ingredients Life Science Ingredients Life Science Ingredients 40% Nutritional supplements, food ingredients, Microbial cosmetics, disinfectants Control and agrochemicals Exclusive Custom Synthesis Manufacturing & Biopharmaceuticals Custom manufacturing and development services for active ingredients Performance Intermediates Custom Manufacturing Development Services Biological Manufacturing Chemical Manufacturing Bioscience Therapeutic Cell Solutions Testing Solutions Research Solutions Bioscience 8% Biology-based products for customers in R&D, production and quality control Life Science Ingredients Nutritional supplements, food ingredients, cosmetics, disinfectants and agrochemicals
4 slide 4 Our broad offering enables us to meet the diverse needs of our customers Technologies Locations Products & Experience Advanced Chemical Synthesis Peptide Synthesis Microbial Fermentation Microbial Biopharma Mammalian Cell Culture Cell Therapy & Custom Media Visp, Switzerland Nansha, China Braine l Alleud, Belgium Visp, Switzerland Kouřim, Czech Republic Nansha, China Kouřim, Czech Republic Visp, Switzerland Visp, Switzerland Hopkinton, MA (USA) Kouřim, Czech Republic Slough & Cambridge, UK Portsmouth, NH (USA) Porriño, Spain Singapore Walkersville, MD (USA) Verviers, Belgium Singapore Synthetic therapeutic small molecules (GMP/ISO) Highly Potent APIs / Antibody drug conjugates (ADCs) Small molecules (biotransformation) Continuous Flow / MicroReactor technology Synthetic peptides (liquid + solid phase) Recombinant DNA peptides Therapeutic proteins (oral & topical) Metabolites (fermentation) Non-parenteral fermented ingredients Industrial enzymes Therapeutic proteins (injectable & oral) Antibody fragments Vaccines (protein antigen & bacterial vector) Plasmid DNA Monoclonal antibodies Therapeutic proteins Cell-based therapeutics Custom liquid and powdered media & buffers UltraPAK bioprocess containers CELL-Tainer single use bioreactor Viral-Based Therapeutics Houston, TX (USA) Viral vaccines / vectors
5 slide 5 Our biologics facilities, products and services are global and leading-edge Houston Hopkinton, MA (USA) Microbial Biopharma 40L to 2,800L cgmp Process R&D Services Walkersville Houston, TX (USA) Viral-based Therapeutics Phase 1-3 Process R&D Services Portsmouth, NH (USA) Mammalian Cell Culture 1,500L to 20,000L cgmp Portsmouth Hopkinton Verviers, BE Slough, UK Porriño, SP Walkersville, MD (USA) Cell Therapy Autologous & Allogeneic Cell Bioassays & Reagents Process R&D Services Media Custom Media & Buffers Bioprocess Containers Slough (UK) Mammalian Cell Culture 200L to 2,000L cgmp Process R&D Services Applied Protein Services Porriño (Spain) Mammalian Cell Culture 4 x 10,000L cgmp Kouřim, CZ Visp, CH Visp (Switzerland) Microbial Biopharma 20L to 15,000L cgmp Process R&D services Microbial Fermentation Process R&D Services Verviers (Belgium) Cell Therapy Autologous & Allogeneic Cell Bioassays, Reagents Process R&D Services Media Custom Media & Buffers Bioprocess Containers Kouřim (Czech Republic) Microbial Fermentation 75L to 75,000L cgmp Process R&D Services Singapore Tuas (Singapore) Mammalian Cell Culture 4 x 20,000L cgmp Process R&D Services Cell Therapy Autologous & Allogeneic Cell Bioassays & Reagents Process R&D Services
6 slide 6 We offer a full range of development and cgmp manufacturing services Discovery Development Manufacture Distribution basic research disease discovery drug discovery drug development clinical trials production packaging marketing sales distribution pre-development screening cell line construction cgmp cell banking lab supply clinical supply process development scale up launch supply in- market supply cgmp manufacturing support for regulatory submissions
7 slide 7 Complexity by molecular weight Chemical Molecule Peptide Protein Antibody Virus Cell / Tissue Increasing Molecular Weight (MW)
8 Mammalian Biologics: Client base and operations From Small Biotech to Large Pharma US, EU, Japan, Australia 100+ projects on-going in process development and manufacturing 20+ years of experience in mammalian cell technology MAbs, Recombinant Proteins slide 8
9 slide 9 Mammalian Biologics: Portfolio of Services Build to buy Commercial manufacturing Clinical manufacturing & IND support Process Development Cell Line creation Multiple potential points of entry and exit for clients
10 Cell Line creation Supported from UK and now Singapore Latest GS TM expression systems and cell lines available CHO K1, NS0 cell types typically used Productivity for MAb s up to 5g/L is typical In-house cell line and expression system development will increase productivity in the future targeting 10g/L in 14 days Process can start with just an ed DNA sequence for the product Transfection, clone selection and MCB creation in 30 weeks slide 10
11 Process Development Upstream Chemically defined cell culture media, animal component free Laboratory scale bioreactor development proven to scale from 200L through to 20,000L Productivity increased through fed-batch culture and precisely controlled operating conditions Downstream Experience of huge range of chromatography techniques, matrices and filtration technologies Scale up experience to 2.0m columns In-house platform technology development will increase process productivity in the future slide 11
12 Clinical manufacturing Experience from 200L through to 5,000L for early phase clinical supply UK, US, Spain and Singapore sites Stirred tank technology, disposable systems, air-lift Experience from 200L through to 20,000L for late phase clinical supply Appropriate CMC packages supplied to support submissions slide 12
13 Commercial manufacturing Commercially licensed products are made in UK, US, ES and once completed, Singapore Successful inspection history for US FDA, EU EMEA, Japanese PMDA plus many more Variety of scales offered 500L through to 20,000L CMC support provided for BLA, EMEA submission Documentation, process validation packages, process support slide 13
14 slide 14 Build to buy Lonza organises the construction, start up, validation, operation and licensing of a new facility Lonza to design facility. Emphasis on leveraging Lonza s existing processes, equipment, design and operation (both technical and quality) for speed and cost benefit Customer platform process can be part of design basis Facility purchase price is fixed Lonza profit based on milestone achievement through to Regulatory Approval
15 slide 15 Technology Transfer experience Between the mid 90 s and the end of 2010, Slough has had experience of transferring over a hundred and twenty processes into and out of it s facilities in the UK In the same period, Portsmouth US has had experience of transferring 35 processes into and out of it s facilities Since 2008 Porrino had 6 transfers and Singapore has had one in each plant Process Transfers to Mammalian Manufacturing - February 2011 Each site has dedicated MSAT (Manufacturing Science and technology) teams in place for these activities UK Forecast US Forecast Porriño Forecast Singapore Forecast UK Complete US Complete Porriño Complete Singapore Complete 10 There is a documented and proven TT protocol
16 slide 16 Singapore facility construction and start-up Build to buy Commercial manufacturing Clinical manufacturing & IND support Process Development Cell Line creation
17 Lonza Singapore operations Facility 1 Build to buy for Genentech/Roche Mammalian cell culture Manufacturing for commercial operations only Facility 2 Typical Lonza CMO model Mammalian cell culture Process Development Manufacturing for clinical development Manufacturing for commercial operations Cell Therapy slide 17
18 slide 18 Lonza facility 1 - Build to buy model Large Scale cell culture production facility dedicated for the production of Avastin for Genentech / Roche Genentech held an option to purchase the facility GMP operations in mid 2009 Staff of 300+ Roche exercised purchase option in Aug 2009
19 slide 19 Key principles design and build Lonza to design facility. Emphasis on leveraging Lonza s existing processes, equipment, design and operation for speed and costs Customer platform process can be part of design basis Facility purchase price is fixed. Customer gets visibility to challenge but Lonza assumes benefit / risk for actual facility cost Lonza to procure equipment / services, build and directly fund facility Customer to fund the capital based on agreed milestone achievements e.g. shell completion, mechanical completion successful pilot batch, successful PV series etc Lonza profit based on milestone achievement through to regulatory approval
20 Facility design and build approach Specification of equipment and systems per Lonza standard Use of previously qualified Lonza vendors for equipment fabrication, automation and building works Example considerable advantage in using Lonza automation platform (Emerson Delta V) which may not be customer standard Customer would have every opportunity to review the quality and implementation of these in real life model (Lonza US, Singapore Facility 2) slide 20
21 Progress checks / Quality Assurance Lonza believes that customer should have every opportunity to review facility progress and adherence to agreed standard Progressive engineering design reviews at agreed milestones Review of selected vendors Mechanical completion inspections Regular engineering reviews to give customer assurance that Lonza is building to agreed specification Typically takes place progressively as construction nears completion Thorough due diligence at facility purchase slide 21
22 Key principle operational enablement Lonza recruits and trains employees Validation, commissioning and facility start-up led by Lonza using Lonza quality systems All operating costs and net working capital costs (raw materials for runs etc) are reimbursed at cost on a recurring basis Lonza can provide additional support and services if required (e.g. tech transfer, pilot, engineering, PV batches) under supplemental agreements at agreed rates Migrate from Lonza quality systems after PAI, if desired slide 22
23 Typical milestone structure Milestones to be agreed based on Lonza s ability to construct, startup and deliver an approved facility Time based with an agreed window for completion e.g. FDA approval between June and December 2018 is 100% achievement, with sliding scale beyond this date Milestones to be split into capital and operational milestones slide 23
24 Key principle facility purchase Full commitment to facility purchase required, or In lieu of purchase, Lonza may consider entering into a long term take or pay supply agreement 100% capacity of facility for 10 years at an agreed batch price slide 24
25 slide 25 Lonza facility 2 typical CMO model Cell culture production facility - multi product, campaign based, contract manufacturing, Multiple scales of operation 200L to 20,000L Multiple technology transfer programs in progress Currently 249 staff and rising to 300 when at full capacity
26 slide 26 Cell Therapy and Process Development Cell culture facility for Cell Therapy operations on Level 2 Process Development and analytical services operations on Level 1 Construction ongoing completion for operations in Q Cell Therapy staff to 60 when at full capacity, R&D staff to 30+ at full capacity Space available for further expansion as required
27 Facility concept Cell culture production facility essentially copy the Lonza plant in Portsmouth, USA Commercially successful High success rate campaigns Multiple successful global, FDA and EMEA regulatory inspections Cell therapy production essentially copy the Lonza plant in Walkersville, USA Both plants leverage existing designs, know-how and documentation into the new facility design Incorporate all lessons learned from multiple years of GMP operation Flexible operations at a variety of scales Re-use proven process technology and quality systems, localize infrastructure Lonza Biologics Confidential slide 27
28 slide 29 Large scale cell culture production successfully completed on time & within budget Civil Design, Permitting Construction of Shell Engineering Design Order Long Lead Equipment GO Decision Construction Fit Out Start Up/Validation Employee Training Group 1 Employee Training Group 2 Pilot & Engineering Runs GMP Production Submission & Inspection Approval Approximately 3 years from Go decision point to full GMP operations
29 Singapore operations status Operational Process Development Small Scale non-cgmp Pilot Operations Large Scale cgmp Manufacturing for Clinical/Commercial Supply at 5,000-20,000L scale In progress through Q Small Scale cgmp Manufacturing for Clinical/Commercial Supply at 200-1,000L scale Q cgmp Cell Therapy Operations Q slide 30
30 Start-up challenges & strategies: General First of its kind plant in Singapore Everything was being done for the first time at this scale Learning curve was steep for everyone involved employees, contractors, agencies Strategy Site Leadership was an equal mix of Lonza expats & local employees Entire Lonza Site Leadership Team migrated from Facility 1 to Facility 2 after divestment Vast majority of staff were local but some key technical positions from other Lonza sites - Manufacturing, MSAT, Engineering, QC Short term assignees from the Lonza network bridged any gaps Lessons learnt meticulously recorded and followed up between facilities slide 31
31 Start-up challenges & strategies: Design & engineering Design & engineering Significant amounts of new / large scale equipment for the region Multiple locations for engineering and skid construction Time difference Strategy Designed to minimize learning curve the design around process equipment was kept intact compared to design as you go Identical naming convention, similar equipment design, flow paths etc Sequences were successful from the word Go Short Term assignees from other sites were very familiar with the Singapore setup ease of commissioning, training Time difference was converted to an advantage. US operations provided support during Singapore nights Ensured 24 x 7 coverage + leveraged on experience slide 32
32 Start-up challenges & strategies: Change management Changes impact schedule & cost Later and more frequent the changes, the more the impact Strategy Clear definition of Scope and buy-in from all stakeholders Changes thereafter had to be defended by the Change agent Changes proposed were critically evaluated for benefit vs. impact Common focus on deliverables and milestones Schedule and status was communicated regularly to the entire site via town hall meetings, C&V updates Rigorous oversight slide 33
33 Start-up challenges & strategies: Resources Manpower for operations (Biotechnologist levels) Non-availability of local workforce trained in biologics manufacturing Knowledge of cgmp for biologics from existing Pharma industry Fresh graduates with engineering / biochemical backgrounds Strategy Utilized Singapore EDB s TAP and STRAT schemes to train local graduate employees Multiple waves sent to other Lonza sites (UK, US, Spain) for training in biologics for up to 18 months both for Facility 1 & 2 Manufacturing, QA, QC, MSAT and Engineering Hired back in Singapore once successfully completed the program(s) Continued training and personal development slide 34
34 Start-up challenges & strategies: Resources Supervisory & middle management resources Limited supply of candidates capable of manning supervisory positions No previous opportunities to gain experience in biologics manufacturing Strategy Rigorous selection process focused on internal candidates Internal leadership training program established to facilitate the jump Targeted at Manufacturing initially and expanded to other technical areas Intense training schedule + training stints in multiple Lonza mammalian sites + mentorship slide 35
35 Start-up challenges & strategies: Resources Manpower for Start-up activities Need personnel familiar with systems to minimize snags / troubleshoot Training on equipment operation Strategy 100+ trained personnel were involved in walking systems down C & Q protocols were executed mostly in-house. Progressively increasing familiarity with systems walk-down, commissioning, executing protocols etc. Experienced short term assignees from other Lonza sites to lead and train significantly higher in Facility 1 - much lesser in Facility 2 the core team had progressed much further in terms of experience and confidence slide 36
36 Start-up challenges & strategies: Systems training Policies / SOPs / Training / Quality Systems Quality Systems, Policies and SOPs need to be developed and made effective for training to be completed Critical to start-up and GMP Commissioning Strategy Facility 1 and Facility 2 Quality Systems, Policies and SOPs were harmonized with Lonza US Most of the process systems were identical Key advantage of the Facility Concept Training by short term assignees from Lonza US Lonza US for critical operations in Facility 1 Expertise of other sites such as Spain and UK utilized for training in Facility 2 critical operations slide 37
37 Start-up challenges & strategies Go clean Setting up an EM Program - Disinfection Ineffective disinfection cycle or disinfectants could cause delays to the ability to maintain classification in clean rooms and consequently HVAC qualification and GMP commissioning Strategy Disinfection program modeled after Lonza US Disinfectant efficacy studies were conducted earlier on in Facility 1. Knowledge gained in Facility 1 was useful in Facility 2 Right choice of disinfectants and cycles No delays to GMP Commissioning slide 38
38 slide 39 Start-up challenges & strategies: Go clean Cleaning of GMP areas Steep learning curve for GMP cleaners Literacy needs vs. fit / willingness to work High turnover of cleaning crew Strategy Many training sessions + frequent refresher sessions Handholding of cleaning contractor to set up a sustainable program Contractor selection + training was initiated 2 months ahead of the first go-clean in Facility 2. GMP Cleaning commenced more than a month before go-clean Float cleaners identified and trained from the general custodial cleaning crew. Incentive program to promote retention made to feel valued part of the overall team
39 Start-up challenges & strategies: Raw materials Raw material sourcing Challenge to establish Supply Chain, identify and qualify local sources Vendor qualification, generation of Raw Material Specifications are typically time critical Long lead times for basic raw materials Strategy Supply Chain was established early on with assistance from Lonza US Material Review Board met weekly to prioritize and review progress Entire flow of raw materials from BOM creation to release of raw material were clearly visible to all stakeholders for each item status was known and bottlenecks identified quickly Assistance from other Lonza sites alleviated schedule constraints for some materials slide 40
40 Overall lessons learnt Getting Goals and Expectations Clear and Agreed Making sure everyone is on the same page and each team understands its role and how it connects to site Ensuring transparency of the validation program planning and execution Connecting capital project team and the operational team to align expectations and standards Maintaining continuity and harmonisation with the rest of the Lonza network Quality procedures and site audit follow-ups need to be monitored carefully Operational practices can change / be upgraded Regular site to site updates all departments Short term assignees help slide 41
41 Overall lessons learnt Raw materials Start procurement early for the operational start-up Leverage the network to minimise lead times Leveraging the Lonza network Successful internal collaboration across the network was critical for success in all areas All the various groups within Lonza contributed the overall success of the projects in Singapore slide 42
42 Conclusion Lonza is able to support clients for mammalian biologics using a number of flexible business models Two facilities constructed and operational in Singapore Key was / is to leverage the global manufacturing network Standardise on as much as possible / only change what you must slide 43
Our passion is to deliver sustainable value to our customers 2007 First Half Results 26 July 2007
Our passion is to deliver sustainable value to our customers 2007 First Half Results 26 July 2007 Toralf Haag Chief Financial Officer Disclaimer Certain matters discussed in this presentation may constitute
More informationLFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals
LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals MAbLaunch TM is a joint bioproduction platform combining LFB Biomanufacturing (LFB
More informationHighly Potent APIs The right platform, people and procedures for successful development and manufacturing
Pharma&Biotech Highly Potent APIs The right platform, people and procedures for successful development and manufacturing Custom Manufacturing and Development Services for Highly Potent APIs Pharma&Biotech
More informationLFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals
LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals MAbLaunch TM is a joint bioproduction platform combining LFB Biomanufacturing (LFB
More informationValentina Gualato, Ph.D. Process Development Scientist
COMPANY PRESENTATION Quality and Innovation Valentina Gualato, Ph.D. Process Development Scientist MISSION areta international is a biotech company dedicated to the contract development and manufacturing
More informationEden Biodesign ebook Monoclonal Antibody Production: Building the Platform
Eden Biodesign ebook Monoclonal Antibody Production: Building the Platform CHAPTER 1: Overview CHAPTER 2: Challenges CHAPTER 3: Purification Methodology CHAPTER 4: Results CHAPTER 5: About Eden Biodesign
More informationDedicated Project Management
Peptides Dedicated Project Management At Lonza, we are committed to our customers success, so it is our mission to help your product reach its full potential. We pride ourselves on delivering high-quality,
More informationThe Importance of Developing a High Yield of Product
European Antibody Congress Lyon, 3 rd November 2005 The Importance of Developing a High Yield of Product John Birch, Lonza Biologics plc Monoclonal Antibodies A Success Story Fastest growing segment of
More informationTechnology Transfer of CMC Activities for MAb Manufacturing. 2010 ge healthcare (www.gelifesciences.com)
M a n u f a c t u r i n g OPERATIONS Technology Transfer of CMC Activities for MAb Manufacturing by Patricia Seymour, Susan Dana Jones, Howard L. Levine With combined 2009 revenues estimated to be over
More informationBiotechpharma company profile
Biotechpharma company profile October 2013 1 History 2004 Biotechpharma UAB established as a proteomic research company in Vilnius, Lithuania 2005 Company became a member of UK s Northway group, investing
More informationNEW CHEMICAL ENTITIES
NEW CHEMICAL ENTITIES PIONEERING PARTNER FOR PEPTIDES With more than 40 years of expertise in peptide synthesis, a track record in process development, large-scale manufacturing and outstanding product
More informationLuca Romagnoli, Ph.D. Business Development Manager
Modelli innovativi di produzione per lo sviluppo di un processo altamente qualitativo di farmaci biologici Luca Romagnoli, Ph.D. Business Development Manager BIOLOGICAL DRUGS - SOURCES Monoclonal antibodies
More informationBiomanufacturing Vision for the Future
Biomanufacturing Vision for the Future Shou-Bai Chao, Ph.D. Senior Vice President Global Manufacturing and Technical Operations MedImmune (a Div of AstraZeneca) NIPTE/FDA Research Conference Future of
More informationBest Practices In Ensuring Quality Standards When Outsourcing To Contract Manufacturers, Licensees And Consultants
Best Practices In Ensuring Quality Standards When Outsourcing To Contract Manufacturers, Licensees And Consultants Alex D. Kanarek, PhD BioProcess Technology Consultants, Inc. Strategic Institute Quality
More informationFrom Research Services and Process Development to GMP Manufacturing
From Research Services and Process Development to GMP Manufacturing P a r ag o n B i o s e r v i c e s, I n c. A contract research and GMP manufacturing organization (CMO) with a focus on the development
More informationManufacturing CUSTOM CHEMICALS AND SERVICES, SUPPORTING SCIENTIFIC ADVANCES FOR HUMAN HEALTH
Manufacturing CUSTOM CHEMICALS AND SERVICES, SUPPORTING SCIENTIFIC ADVANCES FOR HUMAN HEALTH VWR enables the advancement of science by providing high-quality chemicals and services, customized to your
More informationBIOTECH MANUFACTURING SOLUTIONS 4 YOUR SUCCESS. a Novartis company
a Novartis company BIOTECH MANUFACTURING Sandoz GmbH Biotech Cooperations 6250 Kundl Austria Biochemiestrasse10 Phone +43 (0)5338 200 2609 Fax +43 (0)5338 200 442 biotech.cooperations@sandoz.com www.sandoz.com
More informationProviding Trusted and Innovative Solutions t o the Life Science Communities
Providing Trusted and Innovative Solutions t o the Life Science Communities Eurogentec Eurogentec is a leading supplier of trusted and innovative reagents, kits, specialty products and custom research/development
More informationBIOTECHNOLOGY OPERATIONS
BIOTECHNOLOGY OPERATIONS Principles and Practices Michael J. Roy TECHNISCHE INFORMATION SBIBLIOTHEK UNIVERSITATSBIBLIOTHEK HANNOVER CRC Press TaylorStFrancis Croup Boca Raton London New York CRC Press
More informationPresented at: Jefferies 2015 Global Healthcare Conference
Presented at: Jefferies 2015 Global Healthcare Conference Agenda 1 Overview & Service Platforms 2 Adaptability, Scalability & Expansion Plans 3 Best Practices 4 Blue Chip Customer Base 5 Roadmap of Evolution
More informationTriskel: a strategic consulting firm for biopharmaceutical companies
BioStart : Manufacturing and operations in Biotech Strategic stakes and technology evolution in recombinant protein production APFL May 14 th, 2009 François LAWNY Triskel Integrated Services Geneva, Switzerland
More informationBioprocessing Media and Buffers Grow with Us
Bioprocessing Media and Buffers Grow with Us Experience Highly experienced media on the selection of standard media as well as development This service packaging, documentation Leading position in single-use
More informationAccelerating drug development to FTIH: Potential of new expression technologies
Accelerating drug development to FTIH: Potential of new expression technologies Lekan Daramola Associate Director Biopharmaceutical Development, Cell Culture & Fermentation Sciences CMC Strategy Forum
More informationPreparing for the Pre-Approval Inspection What to do Before the FDA Arrives. Barry A. Friedman, Ph.D. Consultant
Preparing for the Pre-Approval Inspection What to do Before the FDA Arrives Barry A. Friedman, Ph.D. Consultant FDA Overview FDA is a consumer protection agency within the Department of Health & Human
More informationManufacturing process of biologics
Manufacturing process of biologics K. Ho Afssaps, France 2011 ICH International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use 2011 ICH 1 Disclaimer:
More informationCompany Presentation
Company Presentation DISCLAIMER This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of amp biosimilars
More informationCatalent Biologics & Clinical Supplies The SMART Solution
Catalent Biologics & Clinical Supplies The SMART Solution Advanced Technology and Integrated Solutions From DNA to Clinical Supply & Cold Chain Distribution Dr. Florian Schwaak Account Manager Germany
More informationIntroduction to Bioprocessing
Introduction to Bioprocessing Cambridge Healthtech Institute Peptalk Palm Springs, CA Presented by Susan Dana Jones and Sheila Magil BioProcess Technology Consultants www.bptc.com BioProcess Technology
More informationMultiple Products in a Monoclonal Antibody S88.01 Batch Plant
Presented at the World Batch Forum North American Conference Chicago, IL May 16-19, 2004 900 Fox Valley Drive, Suite 204 Longwood, FL 32779-2552 +1.407.774.0207 Fax: +1.407.774.6751 E-mail: info@wbf.org
More informationC 5. chemical development contract research custom synthesis cgmp API manufacturing commercial production. Welcome to
C 5 chemical development contract research custom synthesis cgmp API manufacturing commercial production Welcome to ChemCon Company profile Company profile ChemCon offers outstanding chemical services
More informationTable of Contents. Presented by
Improving Markets, Services, and Technologies Table of Contents Presented by HighTech Business Decisions 3150 Almaden Expressway, Suite 222, San Jose, CA 95118 Tel: (408) 978-1035 Fax: (408) 978-8925 www.hightechdecisions.com
More informationPHARMACEUTICAL OUTSOURCING:
PHARMACEUTICAL OUTSOURCING: QUALITY MANAGEMENT AND PROJECT DELIVERY Trevor Deeks, Karen Ginsbury and Susan Schniepp Editors CONTENTS Preface 1 OVERVIEW OF OUTSOURCED OPERATIONS Susan Schniepp 2 LEGAL ASPECTS
More informationBioBusiness Biopharmaceutical Ingredients Recombinant albumins & albumin fusion Dermot Pearson, Strategic Product Director, NZ Biopharma
BioBusiness Biopharmaceutical Ingredients Recombinant albumins & albumin fusion Dermot Pearson, Strategic Product Director, NZ Biopharma 2 Novozymes solutions dedicated to the biopharmaceutical industry
More informationPX Therapeutics : the partner for early stage biotherapeutics development Biotuesday, May 5 2009
PX Therapeutics : the partner for early stage biotherapeutics development Biotuesday, May 5 2009 Christelle Dagoneau, PhD Business Development Director Company Profile Protein expert incorporated in 2000
More informationProduction in an Innovation Economy: The Globalization of Biomanufacturing and Implications for the Geography of Innovation
Production in an Innovation Economy: The Globalization of Biomanufacturing and Implications for the Geography of Innovation Industry Studies Association Pittsburgh, June 1, 2011 Elisabeth Reynolds, Ph.D.
More informationManufacturing Cellular Products for International Clinical Trials
Manufacturing Cellular Products for International Clinical Trials Q U A L I T Y A N D O P E R A T I O N S T R A C K 7 4 / 2 5 / 1 4 1 3 : 4 5-1 5 : 1 5 Olive J Sturtevant, MHP,MT (ASCP)SBB, CQA Director
More informationThe authors: Howard L. Levine, Ph.D., President and Founder. Thomas C. Ransohoff, Senior Consultant
The authors: Howard L. Levine, Ph.D., President and Founder Dr. Levine has over 20 years of experience in the biopharmaceutical industry. Prior to founding BioProcess Technology Consultants to provide
More informationGenScript USA Inc. Open Position List
GenScript USA Inc. is a world leader in developing and marketing innovative biotechnology products. Our dedication to innovation has led GenScript to generate a continuous flow of services and products
More informationBrand Quality with Asian Advantages
Brand Quality with Asian Advantages ScinoPharm Taiwan, Ltd. No.1, Nan-Ke 8th Road, Tainan Science Park, Shan-Hua, Tainan, 74144, Taiwan TEL : 886-6-505-2888 FAX : 886-6-505-2898 Email Contact : mkt@scinopharm.com
More informationPharma & Biotech processes: global turnkey solutions
Pharma & Biotech processes: global turnkey solutions 02 Our mission: to design and build turnkey process solutions AS A LEADING-EDGE INDUSTRIAL INTEGRA- TOR, BOCCARD DESIGNS AND BUILDS UNIQUE PHARMACEUTICAL
More informationPharmaceuticals Production Services Boehringer Ingelheim. Our expertise in world-class contract manufacturing for your success
Pharmaceuticals Production Services Boehringer Ingelheim Our expertise in world-class contract manufacturing for your success Successful partnership Dr Wolfram Carius Head of Corporate Division Pharmaceuticals
More informationAccelerating Antibody Process Development: Exploring the Synergies Between Engineered Host Cells and Process Development
Pharma&Biotech Accelerating Antibody Process Development: Exploring the Synergies Between Engineered Host Cells and Process Development James Rance PhD Head of Development Services Singapore Lonza Biologics
More informationPeptide purification strategies
Särö Conference 2009 Peptide purification strategies Ulf Altenhöner Lonza Exclusive Synthesis R&D Outline Introduction Integrated process development Model-based process development Inspiration Conclusions
More informationA World of Biomanufacturing: Shortages or Global Glut?
A World of Biomanufacturing: Shortages or Global Glut? Howard L. Levine, Ph.D. BioProcess Technology Consultants, Inc. BioProcess International Conference Vienna, Austria May 19-20, 2010 Steady growth
More informationMonoclonal Antibody Production: Building the Platform. Andrew Clutterbuck Eden Biodesign Ltd.
Monoclonal Antibody Production: Building the Platform Andrew Clutterbuck Eden Biodesign Ltd. Questions Questions are encouraged throughout the presentation and can be asked by using the email address provided
More informationPlantForm Corporation
PlantForm Corporation Professor J. Christopher Hall CSO PlantForm Corporation Canada s Top10 Winner Life Sciences 2008/9 Innovator of the Year Guelph, Canada, 2010 Opportunity The introduction of more
More informationBiopharmaceutical Process Evaluated for Viral Clearance
Authored by S. Steve Zhou, Ph.D. Microbac Laboratories, Inc., Microbiotest Division The purpose of Viral Clearance evaluation is to assess the capability of a manufacturing production process to inactivate
More informationVaccine Manufacturing Facilities of the Future. Howard L. Levine, Ph.D. Vaccines Europe London, England December 1 2, 2010
Vaccine Manufacturing Facilities of the Future Howard L. Levine, Ph.D. Vaccines Europe London, England December 1 2, 2010 Challenges in the Production of Vaccines Different technology platforms make it
More informationChallenges in the cgmp Manufacturing of hescs: Lessons Learned from Monoclonal Antibodies
Challenges in the cgmp Manufacturing of hescs: Lessons Learned from Monoclonal Antibodies ISCT 2011 Annual Meeting Rotterdam, The Netherlands May 18 21, 2011 BioProcess Technology Consultants www.bptc.com
More informationMAB Solut. MABSolys Génopole Campus 1 5 rue Henri Desbruères 91030 Evry Cedex. www.mabsolut.com. is involved at each stage of your project
Mabsolus-2015-UK:Mise en page 1 03/07/15 14:13 Page1 Services provider Department of MABSolys from conception to validation MAB Solut is involved at each stage of your project Creation of antibodies Production
More informationVoluntary Genomic Data Submissions at the U.S. FDA
Voluntary Genomic Data Submissions at the U.S. FDA International Conference on Harmonization Chicago, IL November 9-10, 9 2005 Felix W. Frueh, PhD Associate Director for Genomics Office of Clinical Pharmacology
More informationThe Ever-increasing Complexity of Biotech Changes - A Pledge for Global Convergence
The Ever-increasing Complexity of Biotech Changes - A Pledge for Global Convergence CMC Strategy Forum, Sorrento, May 7th, 2014 Susanne Ausborn, Pharma Technical Regulatory Policy F. Hoffmann-La Roche,
More informationDr.ssa Maria Luisa Nolli CEO
IL RUOLO DELLE PICCOLE E MEDIE INDUSTRIE NELLA PROMOZIONE DELLA MEDICINA TRASLAZIONALE Quality and Innovation Dr.ssa Maria Luisa Nolli CEO INTRODUCTION ARETA INTERNATIONAL 12 years of experience in contract
More informationGain efficiency in your process development with ÄKTA avant
Gain efficiency in your process development with ÄKTA avant gelifesciences.com Gain efficiency in your process development with ÄKTA avant Development of efficient manufacturing processes is a necessity
More informationexactly. The need for efficiency in developing effective new therapeutics has never been greater.
exactly. The need for efficiency in developing effective new therapeutics has never been greater. As demands on the global healthcare system increase and treating disease becomes more complex, the research,
More informationConsiderations Impacting the Make vs. Buy Decision
Considerations Impacting the Make vs. Buy Decision Thomas C. Ransohoff BioProcess Technology Consultants, Inc. INTRODUCTION AND BACKGROUND D ecisions related to manufacturing are among the most important
More informationBringing Biotech and Specialty Chemical Expertise to Our Customers
Corporate Pharma&Biotech Bringing Biotech and Specialty Chemical Expertise to Our Customers Richard Ridinger CEO Lonza Corporate Additional Information and Disclaimer Lonza Group Ltd has its headquarters
More informationImproving GS-CHO Cell Line Selection: Reducing Time to Clinic
Cell Line Development and Engineering 2-6 March 2009, Berlin Improving GS-CHO Cell Line Selection: Reducing Time to Clinic Adrian Haines, 2009 Lonza Biologics plc, Slough, UK Disclaimer Certain matters
More informationGenes to Proteins to Antibodies
Genes to Proteins to Antibodies About Us Fusion Antibodies is a CRO established in 2001 as a spin-out from Queen s University Belfast. The company building is situated in a charming area of Springbank
More informationLibrary Guide: Pharmaceutical GMPs
Library Guide: Pharmaceutical GMPs Table of Contents Overview...3 Courses Listed by Functional Area... 4 Course Descriptions: A Step-by-Step Approach to Process Validation (PHDV79)... 7 A Tour of the FDA
More informationRisk-Based Change Management Using QbD Principles
Risk-Based Change Management Using QbD Principles Lynne Krummen, Ph.D. VP, Global Head, Technical Regulatory Biologics Genentech, a member of the Roche Group CMC Forum 2013 Tokyo, Japan Presentation Outline
More informationGuidance for Industry. Monoclonal Antibodies Used as Reagents in Drug Manufacturing
Guidance for Industry Monoclonal Antibodies Used as Reagents in Drug Manufacturing U.S. Department of Health and Human Services Food and Drug Administration enter for Drug Evaluation and Research (DER)
More informationInstitutional Partnership Program
GENEWIZ Outsourcing Services Institutional Partnership Program Solid Science. Superior Service. DNA Sequencing Partners to Fuel Your Success Institutions whose success depends on significant life science
More informationBioservices. Your lab just got bigger
Bioservices Your lab just got bigger Bioservices Expansive bioservices with a global advantage Lonza Bioservices emphasizes accuracy, precision and specificity to provide shortened delivery times and increased
More informationHSA Consumer Guide. Understanding Vaccines, Vaccine Development and Production. www.hsa.gov.sg November 2009. How a Vaccine Works.
November 2009 Understanding Vaccines, Vaccine Development and Production Vaccines, in general, help protect people from harmful infections before they come in contact with the disease. Vaccines may also
More informationCombination Products. Presented by: Karen S. Ginsbury For: IFF March 2014. PCI Pharma
Combination Products Presented by: Karen S. Ginsbury For: IFF March 2014 Types of products Biological and medical device (freeze dried + syringe dual volume) Medical device and plasma devised product (syringe)
More informationGMP Pharma BV. Netherlands
GMP Pharma BV Netherlands Connecting the European & Indian Pharmaceutical, Biotechnology and Biopharmaceutical Industry for parallel growth and solicitation. About Us: GMP Pharma BV is a multisource organization
More informationCord Blood Licensure. Session 2C: Advanced Cell Therapies April 11, 2013
Cord Blood Licensure Session 2C: Advanced Cell Therapies April 11, 2013 Objectives Describe rationale for cord blood licensure Cite licensure regulations Illustrate a case study of one program s pathway
More informationGenScript USA Incorporation:
New Jersey with a subsidiary site in Nanjing, China. Our dedication to innovation has led GenScript to generate a continuous flow of services and products to ease and Job ID: NJ001 Position: Head of Animal
More information"Small and large molecules bioproduction by mammalian and microbial fermentation"
"Small and large molecules bioproduction by mammalian and microbial fermentation" H.-P. Meyer Bio/PharMOS 2004-23-25 March 2004 Symposium B Business Diversification in Life Science "Small and large molecules
More informationA NUSAGE-PharmEng Pharmaceutical and Biotechnology Training Program
A NUSAGE-PharmEng Pharmaceutical and Biotechnology Training Program Shaping Human Capital for Challenges in the Pharmaceutical Industry CLEANING VALIDATION Instructors Loh Kean Chong Rick Ng Date and Time
More informationBio-Reagents Gene synthesis Peptide Synthesis Protein Expression Antibody Production. Life Science Products and Services
Bio-Reagents Gene synthesis Peptide Synthesis Protein Expression Antibody Production Life Science Products and Services Since 2002, Biomatik has provided worldwide researchers in life science discovery
More informationNUVISAN Pharma Services
NUVISAN Pharma Services CESI MS Now available! 1st CRO in Europe! At the highest levels of quality. LABORATORY SERVICES Equipment update STATE OF THE ART AT NUVISAN CESI MS Now available! 1st CRO in Europe!
More information1 The quality management system (QMS) is the corner stone of compliance to GMP. The QMS is made up of several documents, that when followed ensures the GMP compliance of the process, facility and company.
More informationOptimizing Quality Control / Quality Assurance Agents of a Global Sourcing / Procurement Strategy
Optimizing Quality Control / Quality Assurance Agents of a Global Sourcing / Procurement Strategy Global Pharma Sourcing Conference December 6-7, 2011 Philadelphia, USA Nigel J. Smart, Ph.D. Smart Consulting
More informationProject Portfolio Manager Melbourne, Australia Full Time
Project Portfolio Manager Melbourne, Australia Full Time Exciting opportunity in emerging field of cell based therapies. High growth company with deep experience, international reputation. Executing growth
More informationComparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE
Comparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE Dr. Fulvio CARLOTTI, GNOSIS SpA, Corporate QA Director September 26, 2014 Scope of GMP GMP compliance
More informationCustom Antibody Services
Custom Antibody Services Custom service offerings DNA sequence Plasmid Peptide Structure Protein Peptide Small molecule Cells Spleen Lymphocytes Antigen Preparation Immunization Fusion & Subcloning Expansion
More informationIntegrating Good Manufacturing Practices During the Transition from Clinical Trials to Commercial Manufacturing
Integrating Good Manufacturing Practices During the Transition from Clinical Trials to Commercial Manufacturing By Mark Zemler W H I T E P A P E R Executive Summary In support of our customers, this whitepaper
More informationHarmonizing Change Control Processes Globally
Quality & Compliance Associates, LLC Harmonizing Change Control Processes Globally President Quality & Compliance Associates, LLC When We Deal In A Global Environment, How Do We Design A System That Addresses
More informationReagents, Tools, and Services for Pharma Manufacturing. GMP Grade Advanced Intermediates, and Customized Solutions
Reagents, Tools, and ervices for Pharma Manufacturing MP rade Advanced Intermediates, and Customized olutions ur Expertise, Your uccess Roche Custom Biotech offers a growing portfolio of generic and customized
More informationMontgomery County Community College BIT 123 Techniques and Instrumentation for Biotechnology 4-3-3
Montgomery County Community College BIT 123 Techniques and Instrumentation for Biotechnology 4-3-3 COURSE DESCRIPTION: This course will allow students to gain theoretical and practical, hands-on knowledge
More informationThe majority of pharmaceutical companies in
Pharmaceutical Infrastructure and Industry Professor Che-Ming Teng, Ph.D. National Taiwan University College of Medicine, Taipei, Taiwan The majority of pharmaceutical companies in Taiwan are devoted to
More informationAdvances in Biopharmaceutical and Vaccine Manufacturing Plants
Hitachi Review Vol. 62 (2013), No. 4 267 Advances in Biopharmaceutical and Vaccine Manufacturing Plants Sei Murakami, Dr. Eng. Haruo Suzuki Keisuke Shibuya, Dr. Sc. OVERVIEW: The development of innovative
More informationBIOTECHNOLOGY. about biotechnology
BIOTECHNOLOGY about biotechnology Introduction Biotechnology from humble beginnings based on fermentation processes used to make foods, alcoholic drinks, antibiotics and more recently, speciality chemicals
More informationOne of the greatest challenges facing biopharmaceutical
Monoclonal Antibody Manufacturing Strategies for the 21st Century James Blackwell, Ph.D., MBA Sr. Consultant Thomas Ransohoff, VP and Sr. Consultant Howard L. Levine, Ph.D., President and Principal Consultant
More informationCALCET Company California Consulting Engineering & Technology 14895 E14th St. Ste 340, San Leandro, CA 94578 USA www.calcet.com
CALCET Company California Consulting Engineering & Technology 14895 E14th St. Ste 340, San Leandro, CA 94578 USA www.calcet.com ENGINEERING A PIVOTAL ROLE IN BIOTECHNOLOGY AND PHARMACEUTICAL INDUSTRIES
More informationThermo Scientific PepFinder Software A New Paradigm for Peptide Mapping
Thermo Scientific PepFinder Software A New Paradigm for Peptide Mapping For Conclusive Characterization of Biologics Deep Protein Characterization Is Crucial Pharmaceuticals have historically been small
More informationMicrobiology and Auditing. Don Singer
Microbiology and Auditing Don Singer ASQ Northeast Pharmaceutical GMP/Quality Conference 2011 Through the eyes of a Microbiologist Microbiology Audit = Inspection / Investigation Systematic Auditing Planning
More informationExciting Trends in Bioprocessing
Exciting Trends in Bioprocessing Alfred Doig and Susan Dana Jones, Ph.D. April 20, 2015 BioProcess Technology Consultants, Inc. 12 Gill Street, Suite 5450 Woburn, MA 01801 Exciting Trends in Bioprocessing
More informationApplication Of Quality Metrics In Determining Overall State Of Quality. & The Health Of Associated PQS FDA s Current Thinking
Course Objectives: How does industry use Metrics? FDA Challenges and equirements and Use of Quality Metrics Complexities of Implementation (Industry Feedback) What does it all mean? Key in isk identification
More informationBiopharmaceutical Perspectives of Outsourcing: what are supply chain management issues and opportunities
1 Biopharmaceutical Perspectives of Outsourcing: what are supply chain management issues and opportunities Presented by Dr. Philipp Hess Supply Chain Management Issues and Opportunities 2 1. How do we
More informationPROVIDING CHEMISTS WITH THE RIGHT ELN USING A CUSTOM DEVELOPED TOOL
ELECTRONIC LABORATORY NOTEBOOKS SMI, 30th of January 2008, London PROVIDING CHEMISTS WITH THE RIGHT ELN USING A CUSTOM DEVELOPED TOOL Preliminary rolling out of biologists users: Lessons from LONZA Dr.
More informationDelivering gene therapy to patients
Delivering gene therapy to patients FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements
More information2015 2016 Ph.D. Science & Engineering Positions. Wilmington, DE. Analytical Sciences Wilmington, DE. Sciences Wilmington, DE.
2015 2016 Ph.D. Science & Engineering Positions 1) Synthetic Organic Chemistry Crop Protection Newark, DE 2) Polymer Chemistry Performance Polymers Various 3) Polymer Engineering Performance Polymers Various
More informationSelection of Cell Lines for Manufacturing Therapeutic Antibodies by Flow Cytometric Cell Sorting. Andrew Racher Lonza Biologics
Selection of Cell Lines for Manufacturing Therapeutic Antibodies by Flow Cytometric Cell Sorting Andrew Racher Lonza Biologics Structure of Talk 1. The Problem 2. Possible Solutions 3. Solution Chosen
More informationGlycArt Biotechnology AG From Inception to trade sale and what happened after...
GlycArt Biotechnology AG From Inception to trade sale and what happened after... Dr. Joël Jean-Mairet From the Idea to Spin-off from the Swiss Federal Institute of Technology 1996 At the midst his PhD
More informationRegulatory Submission: Applying GLP in Surgical Efficacy Studies
Regulatory Submission: Applying GLP in Surgical Efficacy Studies Curtis Schondelmeyer, DVM Director Preclinical Veterinary Services and Efficacy and Surgical Research Services Welcome to Toxikon 2 CONFIDENTIAL
More informationEMABling Antibody Production Platform
EMABling Antibody Production Platform An industrial solution for the production of therapeutic antibodies with high cytotoxic activity B IOMANUFACTURING EMABling : A fully integrated development platform
More information